Naperville, IL -- (ReleaseWire) -- 07/08/2013 -- Reportstack, provider of premium market research reports announces the addition of Immupharma Plc - Product Pipeline Review - 2013 market report to its offering
Immupharma Plc - Product Pipeline Review - 2013
Global Market Direct's pharmaceuticals report, Immupharma Plc - Product Pipeline Review - 2013 provides data on the Immupharma Plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Immupharma Plc's corporate website, SEC filings, investor presentations and featured press releases, both from Immupharma Plc and industry-specific third party sources, put together by Global Markets Direct's team.
- Immupharma Plc - Brief Immupharma Plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Immupharma Plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Immupharma Plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Immupharma Plc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Immupharma Plc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Immupharma Plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Immupharma Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Immupharma Plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Immupharma Plc and identify potential opportunities in those areas.
To view the table of contents for this market research report please visit